<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11861713</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1587</article-id><article-id pub-id-type="other">EPV1002</article-id><article-id pub-id-type="pii">S0924933824015876</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Cognitive and social cognitive function in patients with schizophrenia and affective disorder: effects of combining pharmacotherapy with cognitive remediation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sachs</surname><given-names>G.</given-names></name><xref rid="aff3440" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1436" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Erfurth</surname><given-names>A.</given-names></name><xref rid="aff3441" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff3440">
<sup>1</sup>
<institution>Medical University of Vienna</institution>
</aff><aff id="aff3441"><sup>2</sup>1st Department of Psychiatry and Psychotherapeutic Medicine, <institution>Klinik Hietzing</institution>, <city>Vienna</city>, <country>Austria</country></aff><author-notes><corresp id="cor1436"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1562">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S762</fpage><lpage>S762</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824015876a.pdf"/><abstract><sec id="sec8632"><title>Introduction</title><p>In recent decades, there has been increasing interest in neurocognitive function, including non-social and social cognition. Cognitive impairment has a significant impact on functional outcome, especially in schizophrenic disorders, but also in affective and other psychiatric disorders.</p></sec><sec id="sec8633"><title>Objectives</title><p>It is our aim to present the assessment and measurement of cognitive dysfunction through adequate instruments and to evaluate the effects of combining pharmacotherapy and cognitive remediation.</p></sec><sec id="sec8634"><title>Methods</title><p>A review of the modern literature is undertaken and results of own investigations using the Screen for Cognitive Impairment in Psychiatry (SCIP, Sachs G <italic toggle="yes">et al.</italic> Schizophr Res Cogn. 2021 May 12;25:100197; Sachs G&#x000a0;<italic toggle="yes">et al.</italic> Schizophr Res Cogn. 2022 Jun 6;29:100259) are presented and evaluated.</p></sec><sec id="sec8635"><title>Results</title><p>Our data show that it is possible to capture cognitive dysfunction in clinical practice.</p></sec><sec id="sec8636"><title>Conclusions</title><p>After a differentiated assessment of cognitive dysfunction, a specific combination of pharmacotherapy and cognitive remediation should be applied to patients with schizophrenia and affective disorders.</p></sec><sec id="sec8637"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>